Analytical Data
-
Gene name
CCR4
- Application
-
Alternative Names
K5-5 CD_antigen: CD194
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 85% as determined by SDS-PAGE.
-
Uniprot
P51679
-
Expression Region
1-360aa
-
Protein Length
Partial
-
Molecular Weight
44.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCR4 (C-C chemokine receptor type 4) is a G protein-coupled receptor that plays a crucial role in immune regulation, particularly in the migration and homing of T cells. It is predominantly expressed on the surface of T-helper cells, regulatory T cells, and certain subsets of dendritic cells, where it mediates the recruitment of these immune cells to sites of inflammation and infection. CCR4 has gained significant attention in recent years due to its involvement in various pathophysiological conditions, including autoimmune diseases, allergies, and cancer. In tumor microenvironments, CCR4 is often upregulated, facilitating the escape of malignant cells from immune surveillance, thereby contributing to tumor progression and metastasis. Consequently, the CCR4 receptor represents a promising target for therapeutic interventions, particularly in the development of monoclonal antibodies and small molecule inhibitors aimed at enhancing anti-tumor immunity and improving patient outcomes. The engineering and study of CCR4 recombinant proteins allow researchers to investigate its structure, function, and interactions, enabling the identification of potential pharmacological agents that can modulate its activity. Understanding the signaling pathways and biological implications of CCR4 will thus provide valuable insights into designing novel immunotherapies and improving treatment strategies for CCR4-associated diseases. This makes CCR4 recombinant protein research not only relevant to basic immunology but also a critical component of applied medical research aimed at addressing significant health challenges.
